Comparison of Somatostatin Analogues in Metastatic Gastroenteropancreatic Neuroendocrine Tumors from a Bayesian Perspective: The GETNE-TRASGU Study
Introduction: Somatostatin analogues (SSA), octreotide LAR (Oct) and lanreotide autogel (Lan), significantly prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, comparative data are not available and randomized trials comparing both SSAs are unlikely to be conducted.
Aim(s): To compare the efficacy of Oct vs Lan.
Materials and methods: Patients with well-differentiated (Ki67% ≤20%) metastatic GEP-NET treated with first-line SSA alone were included. Therapeutic effects were retrospectively evaluated using Bayesian Cox models with neutral generic priors (normal~mean=0, standard deviation=10). Confounding factors were primary tumor site, Ki67%, hepatic tumor burden, symptoms, bone metastases, alkaline phosphatase, neutrophil-lymphocyte ratio, SSA dose, and progression status prior to SSA; primary end-point was PFS.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.